Initiation of hepatic stellate cell activation extends into chronic liver disease

Abstract Activated hepatic stellate cells (aHSC) are the main source of extra cellular matrix in liver fibrosis. Activation is classically divided in two phases: initiation and perpetuation. Currently, HSC-based therapeutic candidates largely focus on targeting the aHSCs in the perpetuation phase. H...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vincent De Smet, Nathalie Eysackers, Vincent Merens, Mina Kazemzadeh Dastjerd, Georg Halder, Stefaan Verhulst, Inge Mannaerts, Leo A. van Grunsven
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Acceso en línea:https://doaj.org/article/8ea65b2a9036464990e291a1c81feff9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Activated hepatic stellate cells (aHSC) are the main source of extra cellular matrix in liver fibrosis. Activation is classically divided in two phases: initiation and perpetuation. Currently, HSC-based therapeutic candidates largely focus on targeting the aHSCs in the perpetuation phase. However, the importance of HSC initiation during chronic liver disease (CLD) remains unclear. Here, we identified transcriptional programs of initiating and activated HSCs by RNA sequencing, using in vitro and in vivo mouse models of fibrosis. Importantly, we show that both programs are active in HSCs during murine and human CLD. In human cirrhotic livers, scar associated mesenchymal cells employ both transcriptional programs at the single cell level. Our results indicate that the transcriptional programs that drive the initiation of HSCs are still active in humans suffering from CLD. We conclude that molecules involved in the initiation of HSC activation, or in the maintenance of aHSCs can be considered equally important in the search for druggable targets of chronic liver disease.